After EMPA-REG OUTCOME and LEADER: Already a „New Era“ in Therapy of Type 2 Diabetes?

Exp Clin Endocrinol Diabetes 2016; 124(08): 459-460
DOI: 10.1055/s-0042-111316

Editorial

H. Schatz

¹Ruhr University Bochum

Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study)and liraglutide (LEADER Study) and the consequences.

empagliflozin - liraglutid - cardiovascular effects - new era of treatment? - add-on to metformin?

References
1 Tucker M. „New era“ of type 2 diabetes treatment as LEADER unveiled?. http://www.medscape.com/viewarticle/864729_print
2 Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med September 17 2015;
3 Marso SB et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med June 13 2016;
4 Schatz H. Empagliflozin (Jardiance^®), ein SGLT2-Hemmer, verringert signifikant kardiovaskuläre Ereignisse bei Hochrisiko-Typ-2 Diabetes-Patienten. www.blog.endokrinologie.net 18 September 2016
5 Schatz H. Liraglutid senkt kardiovaskuläre Ereignisse bei Typ-2-Diabetes: die Zahlen der LEADER-Studie. www.blog.endokrinologie.net 17 June 2016
6 Eckel RH In: Miriam Tucker: „New era“ of type 2 diabetes treatment as LEADER unveiled?. http://www.medscape.com/viewarticle/864729_print
7 Joshua J. Fenton: Clinicians Should Think Twice Before Prescribing DPP-4 Inhibitors for Diabetes. Evidence Based Medicine 2016; 21: 81-82
8 Wysham CH et al. Cardiovascular outcomes with antihyperglycemic therapy: Past, present and future impact on practice. http://www.medscape.org/viewarticle/864239?src=mkmcmr_driv_s…
9 Rados DV et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016; Apr 13: e1001992 Published online 2016 Apr 12. Corrected: see PLoS Med. 2016 June 24; 13 (6): e1002091